Molecular genetics of chronic obstructive pulmonary disease

Thorax

Volumn 54, Issue 3, 1999, Pages 245-252

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; BLOOD GROUP ANTIGEN; CYTOKINE; PROTEINASE; PROTEINASE INHIBITOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; VITAMIN D BINDING PROTEIN;

ATOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; ETHNIC DIFFERENCE; FAMILY HISTORY; GENOME; HEREDITY; HLA SYSTEM; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFLAMMATORY CELL; MEDIATOR; MOLECULAR GENETICS; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ETHNOLOGY; GENETIC PREDISPOSITION; GENETIC PROCEDURES; GENETICS; PEDIGREE;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TECHNIQUES; HUMANS; LUNG DISEASES, OBSTRUCTIVE; PEDIGREE;

EID: 0033093103     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.3.245     Document Type: Review

References (110)

1. Silverman EK, Speizer FE. Risk factors for the development of chronic obstructive pulmonary disease. Med Clin North Am 1996;80:501-22.
2. Buist AS, Vollmer WM, Wu Y, et al. Effects of cigarette smoking on lung function in four population samples in the People's Republic of China. The PRC-US Cardiovascular and Cardiopulmonary Epidemiology Research Group. Am J Respir Crit Care Med 1995;151:1393-400.
3. 1 and prevalence of pulmonary conditions in Japanese-American men. Am Rev Respir Dis 1988;138:1398-404.
4. Tager I, Tishler PV, Rosner B, et al. Studies of the familial aggregation of chronic bronchitis and obstructive airways disease. Int J Epidemiol 1978;7:55-62.
5. Khoury MJ, Beaty TH, Newill CA, et al. Genetic-environmental interactions in chronic airways obstruction. Int J Epidemiol 1986;15:65-72.
6. Higgins M, Keller J. Familial occurrence of chronic respiratory disease and familial resemblance in ventilatory capacity. J Chronic Dis 1975;28:239-51.
7. Kueppers F, Miller RD, Gordon H, et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med 1977;63:336-42.
8. Rybicki BA, Beaty TH, Cohen BH. Major genetic mechanisms in pulmonary function. J Clin Epidemiol 1990;43:667-75.
9. Givelber RJ, Couropmitree NN, Gottlieb DJ, et al. Segregation analysis of pulmonary function among families in the Framingham Study. Am J Respir Crit Care Med 1998;157:1445-51.
10. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157:1770-8.
11. Redline S, Tishler PV, Lewitter FI, et al. Assessment of genetic and nongenetic influences on pulmonary function. A twin study. Am Rev Respir Dis 1987;135:217-22.
12. Webster PM, Lorimer EG, Man SF, et al. Pulmonary function in identical twins: comparison of nonsmokers and smokers. Am Rev Respir Dis 1979;119:223-8.
13. Hankins D, Drage C, Zamel N, et al. Pulmonary function in identical twins raised apart. Am Rev Respir Dis 1982;125:119-21.
14. Finkelstein R, Fraser RS, Ghezzo H, et al. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995;152:1666-72.
15. Gelb AF, Hogg JC, Muller NL, et al. Contribution of emphysema and small airways in COPD. Chest 1996;109:353-9.
16. Gelb AF, Zamel N, Hogg JC, et al. Pseudophysiologic emphysema resulting from severe small-airways disease. Am J Respir Crit Care Med 1998;158:815-9.
17. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998;53:129-36.
18. Saetta M, Di Stefano A, Turato G, et al. CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:822-6.
19. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995;152:1262-7.
20. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
21. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma and normal subjects. Am J Respir Crit Care Med 1997;155:449-53.
22. Kwon OJ, Au BT, Collins PD, et al. Tumor necrosis factor-induced interleukin 8 expression in cultured human epithelial cells. Am J Physiol 1994;11:L398-405.
23. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
24. Zakrzewski JT, Barnes NC, Costello JF, et al. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis 1987;136:779-82.
25. Hubbard RC, Fells G, Gadek J, et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991;88:891-7.
26. In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
27. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:341-57.
28. Stockley RA. The role of proteinases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med 1994;150:S109-13.
29. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 1994;150:S160-4.
30. Finlay GA, Russell KJ, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalvoelar lavage fluid of emphysematous patients. Thorax 1997;52:502-6.
31. Finlay GA, O'Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997;156:240-7.
32. Shapiro SG, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993;268:23824-9.
33. Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage metalloelastase for cigarette smoke-induced emphysema in mice. Science 1997;277:2002-4.
34. Sallenave JM, Shulmann J, Crossley J, et al. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994;11:733-41.
35. Llewellyn Jones CG, Lomas DA, Stockley RA. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax 1994;49:567-72.
36. Lockhart DJ, Dong H, Byrne MC, et al. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 1996;14:1675-80.
37. Wallace RW. DNA on a chip: serving up the genome for diagnostics and research. Mol Med Today 1997;3:384-9.
38. Daniels SE, Bhattacharrya S, James A, et al. A genome-wide search for quantitative trait loci underlying asthma. Nature 1996;383:247-50.
39. The Collaborative Study on the Genetics of Asthma (CSGA). Genome-wide search for asthma susceptibility loci in ethnically diverse populations. Nat Genet 1997;15:389-92.
40. White JA, Petkovich M. Identification and cloning of RA-regulated genes by mRNA-differential display. Methods Mol Biol 1998;89:389-404.
41. James P. Protein identification in the post-genome era: the rapid rise of proteomics. Q Rev Biophys 1997;30:279-331.
42. Selman M, Montano M, Ramos C, et al. Tobacco smoke-induced lung emphysema in guinea pigs is associated with increased interstitial collagenase. Am J Physiol 1996;271:L734-43.
43. Luisetti M, Pignatti PF. The search for susceptibility genes of COPD. Monaldi Arch Chest Dis 1995;50:28-32.
44. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997;10:1380-91.
45. 1-antitrypsin deficiency. Scand J Clin Invest 1996;15:132-40.
46. 1-antitrypsin deficiency, cirrhosis and emphysema. Thorax 1998;53:501-5.
47. 1-antitrypsin gene and chronic lung disease. Thorax 1990;48:759-64.
48. 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996;154:1718-25.
49. Alvarez-Granda L, Cabero-Perez MJ, Bustamante-Ruiz A, et al. PI SZ phenotype in chronic obstructive pulmonary disease. Thorax 1997;52:659-61.
50. 1-antitrypsin gene and a disease-associated mutation in a related enhancer sequence. Am J Respir Crit Care Med 1994;150:S183-9.
51. 1-antitrypsin gene and chronic obstructive pulmonary disease. J Med Genet 1997;34:874-5.
52. 1-antitrypsin gene polymorphism related to respiratory system disease. Klin Wochenschr 1987;65:538-41.
53. 1-antichymotrypsin gene associated with chronic lung disease. Lancet 1992;339:1538.
54. 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993;17:740-3.
55. 1-antichymotrypsin. Am Rev Respir Dis 1990;141:884-8.
56. 1-antichymotrypsin mutations in patients with chronic obstructive pulmonary disease. Dis Markers 1998;13:257-60.
57. 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet 1992;88:313-9.
58. Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J Clin Invest 1991;87:2207-15.
59. Kuijpers AL, Pfundt R, Zeeuwen PL, et al. SKALP/elafin gene polymorphisms are not associated with pustular forms of psoriasis. Clin Genet 1998;54:96-101.
60. Ludecke B, Poller W, Olek K, et al. Sequence variant of the human cathepsin G gene. Hum Genet 1993;91:83-4.
61. Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995;73:209-15.
62. Folz RJ, Peno-Green L, Crapo JD. Identification of a homozygous missense mutation (Arg to Gly) in the critical binding region of the human EC-SOD gene (SOD3) and its association with dramatically increased serum enzyme levels. Hum Mol Genet 1994;3:2251-4.
63. Sandstrom J, Nilsson P, Karlsson K, et al. 10-fold increase in human plasma extracellular superoxide dismutase content caused by a mutation in heparin-binding domain. J Biol Chem 1994;269:19163-6.
64. Cantlay AM, Smith CA, Wallace WA, et al. Heterogeneous expression and polymorphic genotype of glutathione S-transferases in human lung. Thorax 1994;49:1010-4.
65. Harrison DJ, Cantlay AM, Rae F, et al. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol 1997;16:356-60.
66. Hassett C, Aicher L, Sidhu JS, et al. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421-8.
67. Smith CAD, Harrison DJ. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350:630-3.
68. Cohen BH, Diamond EL, Graves CG, et al. A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet 1977;ii:523-6.
69. Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987;106:512-8.
70. Cantlay AM, Lamb D, Gillooly M. Association between the CYP1A1 gene polymorphims and susceptibility to emphysema and lung cancer. J Clin Mol Pathol 1995;48:M210-4.
71. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Thorax 1998;53:137-47.
72. Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
73. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-α promoter polymorphism effects transcription. Mol Immunol 1997;34:391-9.
74. Louis E, Franchimont D, Piron A, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
75. Huang SL, Su CH, Chang SC. Tumor necrosis factor-α gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997;156:1436-9.
76. Gile LS, Luisetti M, Patuzzo C, et al. TNF-α gene promoter polymorphism in Italian patients with obstructive pulmonary disease. Am J Respir Crit Care Med 1998;159:In press.
77. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997;112:505-10.
78. Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436-45.
79. Stordeur P, Goldman M. Interleukin-10 as a regulatory cytokine induced by cellular stress: molecular aspects. Int Rev Immunol 1998;16:501-22.
80. Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995;96:2304-10.
81. Cox G. IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol 1996;271:L566-71.
82. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8.
83. Lim S, Crawley E, Woo P, et al. Haplotype associated with low interleukin-10 production in patients with severe asthma. Lancet 1998;352:113.
84. Hajeer AH, Lazarus M, Turner D, et al. IL-10 gene promoter polymorphisms in rheumatoid arthritis. Scand J Rheumatol 1998;27:142-5.
85. Gasparini P, Savoia A, Luisetti M, et al. The cystic fibrosis gene is not likely to be involved in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 1990;2:297-9.
86. Artlich A, Boysen A, Bunge S, et al. Common CFTR mutations are not likely to predispose to chronic bronchitis in northern Germany. Hum Genet 1995;95:226-8.
87. Pignatti PF, Bombieri C, Marigo C, et al. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum Mol Genet 1995;4:635-9.
88. Beaty TH, Menkes HA, Cohen BH, et al. Risk factors associated with longitudinal change in pulmonary function. Am Rev Respir Dis 1984;129:660-7.
89. Krzyzanowski M, Jedrychowski W, Wysocki M. ABO blood group system and cigarette smoking: interaction in chronic airways obstruction (letter). Int J Epidemiol 1987;16:293-4.
90. Higgins MW, Keller JB, Becker M, et al. An index of risk for obstructive airways disease. Am Rev Respir Dis 1982;125:144-51.
91. Vestbo J, Hein HO, Suadicani P, et al. Genetic markers for chronic bronchitis and peak expiratory flow in the Copenhagen Male Study. Dan Med Bull 1993;40:378-80.
92. Cohen BH, Bias WB, Chase GA, et al. Is ABH nonsecretor status a risk factor for obstructive lung disease? Am J Epidemiol 1980;111:285-91.
93. Haines AP, Imeson JD, Meade TW. ABH secretor status and pulmonary function. Am J Epidemiol 1982;115:367-70.
94. Kauffmann F, Kleisbauer JP, Cambon-De-Mouzon A, et al. Genetic markers in chronic air-flow limitation. A genetic epidemiologic study. Am Rev Respir Dis 1983;127:263-9.
95. Abboud RT, Yu P, Chan-Yeung M, et al. Lack of relationship between ABH secretor status and lung function in pulp mill workers. Am Rev Respir Dis 1982;126:1089-91.
96. Horne SL, Cockroft DW, Lovegrove A, et al. ABO, Lewis and secretor status and relative incidence of airflow obstruction. Dis Markers 1985;3:55-62.
97. 1, wheezing, and asthma. Am J Respir Crit Care Med 1996;153:76-82.
98. Webb DR, Condemi JJ. Selective immunoglobulin A deficiency and chronic obstructive lung disease. A family study. Ann Intern Med 1974;80:618-21.
99. 3. N Engl J Med 1985;313:720-4.
100. 1 deficiency: common in obstructive lung disease. Hereditary in families with immunodeficiency and autoimmune disease. Monogr Allergy 1986;20:106-15.
101. O'Keeffe S, Gzel A, Drury R, et al. Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J 1991;4:932-6.
102. Metcalf JP, Thompson AB, Gossman GL, et al. Gc globulin functions as a cochemotaxin in the lower respiratory tract. A potential mechanism for lung neutrophil recruitment in cigarette smokers. Am Rev Respir Dis 1991;143:844-9.
103. Braun A, Kofler A, Morawietz S, et al. Sequence and organization of the human vitamin D-binding protein gene. Biochim Biophys Acta 1993;1216:385-94.
104. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive airways disease by the GC2 allele. Hum Hered 1990;40:173-6.
105. Schellenberg D, Pare PD, Weir TD, et al. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998;157:957-61.
106. Pride N. Smoking, allergy and airways obstruction: revival of the 'Dutch hypothesis'. Clin Allergy 1986;16:3-6.
107. Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 1996;153:1802-11.
108. Sandford A, Weir T, Pare P. The genetics of asthma. Am J Respir Crit Care Med 1996;153:1749-65.
109. Moffatt MF, Cookson WO. Gene identification in asthma and allergy. Int Arch Allergy Immunol 1998;116:247-52.
110. Barnes PJ. Chronic obstructive pulmonary disease: new opportunities for drug development. Trends Pharmacol Sci 1998;19:415-3.